AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · IEX Real-Time Price · USD
2.790
-0.060 (-2.11%)
At close: Jul 19, 2024, 4:00 PM
2.819
+0.029 (1.04%)
Pre-market: Jul 22, 2024, 8:36 AM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 41 employees as of December 31, 2023. The number of employees increased by 5 or 13.89% compared to the previous year.
Employees
41
Change (1Y)
5
Growth (1Y)
13.89%
Revenue / Employee
n/a
Profits / Employee
-$1,610,390
Market Cap
83.22M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 41 | 5 | 13.89% |
Dec 31, 2022 | 36 | 14 | 63.64% |
Dec 31, 2021 | 22 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Sangamo Therapeutics | 405 |
CASI Pharmaceuticals | 176 |
Hyperfine | 131 |
AlloVir | 112 |
Verastem | 73 |
BioAtla | 65 |
Benitec Biopharma | 18 |
Genenta Science | 14 |
ANTX News
- 2 months ago - AN2 Therapeutics Reports First Quarter 2024 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 4 months ago - AN2 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 4 months ago - SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of AN2 Therapeutics, Inc. - ANTX - PRNewsWire
- 4 months ago - Levi & Korsinsky, LLP Investigates Possible Securities Fraud Violations by AN2 Therapeutics, Inc. (ANTX) - Accesswire
- 4 months ago - ANTX ALERT: Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by AN2 Therapeutics, Inc. - Accesswire
- 5 months ago - AN2 Therapeutics, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - ANTX - Accesswire
- 5 months ago - AN2 Therapeutics, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - ANTX - Accesswire
- 5 months ago - INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AN2 Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm - Accesswire